Comparison

BoSTT vs iRefer

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

BoSTT

Access a comprehensive library of bone and soft tissue tumor case studies from leading experts. Explore clinical histories, radiology, pathology, diagnoses, and treatment plans. Ideal for healthcare professionals and medical students seeking to expand their knowledge in musculoskeletal oncology.

Highlights
  • Musculoskeletal tumor case studies
  • Clinical history details
  • High-resolution radiology and pathology images
  • Diagnosis and treatment information
  • Learning points for each case
  • Expert-provided content
Features
Read full description

Bone and soft tissue tumours - case studies (BoSTT) is a mobile source of musculoskeletal tumour cases provided by experts at the Royal National Orthopaedic Hospital (RNOH) NHS Trust, Stanmore, Greater London, UK. BoSTT brings the user a real experience of frequent and rare, typical and more unusual cases of bone and soft tissue tumours. Each case has a clinical history, high resolution radiology and pathology images, diagnosis, treatment and learning points. The app is designed for healthcare professional working in the field of musculoskeletal healthcare, including radiologists, pathologists, orthopaedic surgeons, oncologists, nurse specialists and physiotherapists. It can also be used by medical students, trainees, residents and specialist fellows for continuing medical education. The RNOH is the largest orthopaedic hospital in the UK and is regarded as a leader in the field of orthopaedics and sarcoma care both in the UK and worldwide. This App was financed by RNOH's Innovation Fund with the support of the Pathological Society of Great Britain and Ireland.

About

iRefer

Features
Read full description

The iRefer guidelines have been published by the Royal College of Radiologists since 1989 and are aimed at all healthcare professionals to help determine the best, safest and most appropriate imaging investigations. This application provides on the go access to the iRefer guidelines, even when offline.

Screenshots

BoSTT4 screens
iRefer4 screens

Verdict

The call

The clearest difference is in-app purchases: BoSTT at none against iRefer's 1. iRefer's advantage is update cadence (every 6 weeks vs every 7 months). On price, ads, device support and iOS requirement there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. iRefer sells 1 in-app purchase, starting at $149.99 per year. BoSTT asks for nothing beyond the download.

UpkeepUpdate frequency

BoSTT ships an update every 7 months, iRefer every 6 weeks. The most recent releases landed on September 28, 2026 and September 29, 2026 respectively.

Scorecard2 real differences · 8 level
BoSTT versus iRefer: the parameters behind the verdict, then further details
ParameterBoSTTiRefer
PriceFreeFree
Rating5.0 (3 ratings) — better—
Positive reviews100.0% of reviews—
Number of ratings3 — better—
Update frequencyEvery 7 monthsEvery 6 weeks — better
AdsNoNo
In-app purchasesNo — betterYes
MonetizationFree—
DevicesiPhone, iPad, iPodiPhone, iPad, iPod
Requires iOS15.114.0 — better
Further details — not scored
Size40 MB34 MB
Age rating17+17+
DeveloperRoyal National Orthopaedic HospitalThe Royal College of Radiologists

In-app purchases

None

BoSTT

No in-app purchases

1 purchases

iRefer

Subscriptions1
  • iRefer Individual Plan$149.991 Year

Questions

Is BoSTT free?
BoSTT is free to download, with no in-app purchases.
Is iRefer free?
iRefer is free to download, with in-app purchases available.
Do BoSTT or iRefer have ads?
Neither BoSTT nor iRefer shows ads.
Which is updated more often, BoSTT or iRefer?
BoSTT ships an update every 7 months, and iRefer every 6 weeks. Most recently, BoSTT was updated on September 28, 2026 and iRefer on September 29, 2026.

Other comparisons